IN2014CN02518A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN02518A IN2014CN02518A IN2518CHN2014A IN2014CN02518A IN 2014CN02518 A IN2014CN02518 A IN 2014CN02518A IN 2518CHN2014 A IN2518CHN2014 A IN 2518CHN2014A IN 2014CN02518 A IN2014CN02518 A IN 2014CN02518A
- Authority
- IN
- India
- Prior art keywords
- methods
- cells
- compositions
- hematopoietic stem
- present
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000002463 transducing effect Effects 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
- C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161541736P | 2011-09-30 | 2011-09-30 | |
| PCT/US2012/057987 WO2013049615A1 (en) | 2011-09-30 | 2012-09-28 | Compounds for improved viral transduction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02518A true IN2014CN02518A (enrdf_load_stackoverflow) | 2015-07-31 |
Family
ID=47996444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2518CHN2014 IN2014CN02518A (enrdf_load_stackoverflow) | 2011-09-30 | 2012-09-28 |
Country Status (19)
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108379292A (zh) | 2008-11-06 | 2018-08-10 | 印第安纳大学研究与技术公司 | 增强造血干细胞植入过程的材料和方法 |
| SG11201401077PA (en) * | 2011-09-30 | 2014-04-28 | Bluebird Bio Inc | Compounds for improved viral transduction |
| CA2880808C (en) | 2012-08-01 | 2023-01-24 | United Therapeutics Corporation | Treatment of pulmonary arterial hypertension with mesenchymal stem cells |
| EP3492084B1 (en) | 2012-08-01 | 2021-02-17 | United Therapeutics Corporation | Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells |
| US20150216903A1 (en) * | 2012-08-10 | 2015-08-06 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| CA2892860C (en) | 2012-11-27 | 2023-01-03 | Children's Medical Center Corporation | Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction |
| EP3878452B1 (en) | 2013-01-09 | 2023-09-20 | United Therapeutics Corporation | Treatment of vasculopathy with prostacyclin and mesenchymal stem cells |
| KR20160075676A (ko) * | 2013-10-24 | 2016-06-29 | 오스페달레 산 라파엘 에스.알.엘. | 방법 |
| EP3122181A4 (en) * | 2014-03-26 | 2018-04-25 | The Brigham and Women's Hospital, Inc. | Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells |
| CN106794260B (zh) | 2014-04-25 | 2021-02-23 | 儿童医疗中心有限公司 | 治疗血红蛋白病的组合物和方法 |
| JP7288302B2 (ja) | 2015-05-08 | 2023-06-07 | ザ チルドレンズ メディカル センター コーポレーション | 胎児型ヘモグロビン再誘導のための、ｂｃｌ１１ａエンハンサー機能性領域を標的とする方法 |
| RU2630654C2 (ru) * | 2015-07-29 | 2017-09-11 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Балтийский Федеральный Университет имени Иммануила Канта" (БФУ им. И. Канта) | Способ хемогенетической регистрации и коррекции нейрогенеза на основе генетических конструкций для трансфекции астроцитов и нейронов |
| CN105062979A (zh) * | 2015-08-21 | 2015-11-18 | 昆明理工大学 | 一种培养戊型肝炎病毒的方法 |
| US11326183B2 (en) * | 2016-02-12 | 2022-05-10 | Bluebird Bio, Inc. | VCN enhancer compositions and methods of using the same |
| EP3414321B8 (en) * | 2016-02-12 | 2023-05-03 | bluebird bio, Inc. | Vcn enhancer compositions and methods of using the same |
| EP3440191A4 (en) * | 2016-04-07 | 2019-12-11 | Bluebird Bio, Inc. | CHIMERIC ANTIGEN RECEPTOR T-CELL COMPOSITIONS |
| CA3023257A1 (en) | 2016-05-05 | 2017-11-09 | Liquidia Technologies, Inc. | Dry powder treprostinil for the treatment of pulmonary hypertension |
| WO2018080990A1 (en) | 2016-10-24 | 2018-05-03 | United Therapeutics Corporation | Enhancement of msc immunomodulatory properties by treprostinil |
| EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | EXOSOMES FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS |
| US11261441B2 (en) | 2017-03-29 | 2022-03-01 | Bluebird Bio, Inc. | Vectors and compositions for treating hemoglobinopathies |
| EP3600448A4 (en) * | 2017-03-29 | 2021-01-27 | Bluebird Bio, Inc. | VECTORS AND COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES |
| WO2018218135A1 (en) | 2017-05-25 | 2018-11-29 | The Children's Medical Center Corporation | Bcl11a guide delivery |
| US11358968B2 (en) | 2017-09-15 | 2022-06-14 | The Medical College Of Wisconsin, Inc. | Substituted epoxyeicosatrienoic acid (EET) analogs for treatment of kidney disease |
| FR3074189A1 (fr) * | 2017-11-30 | 2019-05-31 | Assistance Publique - Hopitaux De Paris | Methode de generation de greffons de cellules souches hematopoietiques |
| CN109207427B (zh) * | 2018-09-17 | 2020-12-08 | 诺未科技（银川）有限公司 | 一种将人造血祖细胞转变为造血干细胞的方法 |
| CN110799641B (zh) * | 2018-04-13 | 2021-02-19 | 诺未科技（北京）有限公司 | 丁酸钠的用途及含有丁酸钠的培养体系 |
| EP4285921A3 (en) * | 2018-04-27 | 2024-03-06 | The Medical College of Wisconsin, Inc. | Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders |
| EP3787600A4 (en) | 2018-05-02 | 2022-02-16 | The Children's Medical Center Corporation | ENHANCED BCL11A MICRORNAS FOR THE TREATMENT OF HEMOGLOBINOPATHIES |
| EP3849618A4 (en) | 2018-09-14 | 2022-06-29 | The Children's Hospital Of Philadelphia | Compositions and methods for hemoglobin production |
| CN112805015A (zh) * | 2018-10-12 | 2021-05-14 | 生命技术公司 | 造血干细胞和造血祖细胞扩增系统 |
| EP3888693A4 (en) * | 2018-11-30 | 2022-09-21 | Kyoto University | DRUG DELIVERY SYSTEM USING A SOLUTION |
| US20220389448A1 (en) * | 2019-06-28 | 2022-12-08 | The Children's Hospital Of Philadelphia | Compositions and methods for treating anemia |
| WO2021076993A1 (en) * | 2019-10-16 | 2021-04-22 | Orchard Therapeutics (Europe) Limited | Compositions and methods for modifying eukaryotic cells |
| CA3180217A1 (en) * | 2020-06-02 | 2021-12-09 | Gregory T. Bleck | Nucleic acid constructs for protein manufacture |
| CN115125270A (zh) * | 2021-03-22 | 2022-09-30 | 华东师范大学 | 一种α-珠蛋白过表达载体及其应用 |
| CN113106098B (zh) * | 2021-04-21 | 2022-04-01 | 贵州医科大学 | 一种在红系细胞中特异表达人β珠蛋白的重组序列及其应用 |
| AU2021202658A1 (en) | 2021-04-28 | 2022-11-17 | Fondazione Telethon | Gene therapy |
| CN113336833A (zh) * | 2021-06-04 | 2021-09-03 | 广州伯尼兹生物科技有限公司 | 一种高效分泌表达猪流行性腹泻病毒s1蛋白的生产方法 |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| GB202206346D0 (en) | 2022-04-29 | 2022-06-15 | Ospedale San Raffaele Srl | Gene therapy |
| WO2024033802A2 (en) | 2022-08-11 | 2024-02-15 | Fondazione Telethon Ets | Gene therapy |
| EP4602153A1 (en) | 2022-10-11 | 2025-08-20 | Fondazione Telethon ETS | 3d cell culture methods |
| EP4602174A1 (en) | 2022-10-13 | 2025-08-20 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024243340A1 (en) | 2023-05-23 | 2024-11-28 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| IT202300011790A1 (it) | 2023-06-08 | 2024-12-08 | Fond Telethon Ets | Protocolli di manipolazione genica in cellule immunitarie |
| WO2025056970A1 (en) * | 2023-09-12 | 2025-03-20 | Virocell Biologics Ltd | Mammalian cell culture additives |
| WO2025088508A1 (en) | 2023-10-24 | 2025-05-01 | Fondazione Telethon Ets | Means and methods for genetic modification of uba1 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US568159A (en) | 1896-06-26 | 1896-09-22 | Veneering-machine | |
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| US5460964A (en) | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
| WO1993023011A1 (en) | 1992-05-18 | 1993-11-25 | Minnesota Mining And Manufacturing Company | Transmucosal drug delivery device |
| CA2165679A1 (en) | 1993-06-21 | 1995-01-05 | Tim M. Townes | Anti-sickling hemoglobin |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
| US5869039A (en) | 1993-10-15 | 1999-02-09 | Institut National De La Sante Et De La Recherche Medicale | X-linked adrenoleukodystrophy gene and corresponding protein |
| ATE181361T1 (de) | 1994-09-19 | 1999-07-15 | Massachusetts Inst Technology | Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie |
| US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| ES2265153T3 (es) | 1995-09-29 | 2007-02-01 | Indiana University Research And Technology Corporation | Metodos para una transferencia de adn mediada por virus potenciada usando moleculas con dominios de union a virus y celulas. |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6057117A (en) | 1996-04-04 | 2000-05-02 | Chiron Corporation | Identification and use of selective inhibitors of glycogen synthase kinase 3 |
| WO1998000541A2 (en) | 1996-07-03 | 1998-01-08 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of human disease |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| EP1129175A2 (en) | 1998-10-16 | 2001-09-05 | Novartis AG | Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors |
| AU2183900A (en) | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
| US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
| WO2001012596A1 (fr) | 1999-08-13 | 2001-02-22 | Taisho Pharmaceutical Co., Ltd. | Derives de prostaglandine |
| EP2292657A1 (en) | 1999-11-12 | 2011-03-09 | Baxter Biotech Technology S.A.R.L. | Reduced side-effect hemoglobin compositions |
| DE60037905T2 (de) | 1999-12-17 | 2009-01-29 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Pyrazin-basierte hemmer der glycogen-synthase-kinase 3 |
| ES2263557T3 (es) | 2000-01-31 | 2006-12-16 | Pfizer Products Inc. | Uso de agonistas selectivos del receptor 4(ep4) de prostablandinas (pge2) para el tratamiento de insuficiencia renal aguda y cronica. |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| CA2446110C (en) | 2001-05-01 | 2013-06-25 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
| AU2002347563A1 (en) | 2001-12-06 | 2003-06-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders |
| EP1468094A4 (en) | 2001-12-24 | 2005-01-26 | Es Cell Int Pte Ltd | METHOD OF TRANSDUCTING ES CELLS |
| AU2003214920A1 (en) | 2002-02-04 | 2003-09-02 | Millennium Pharmaceuticals Inc. | Methods and compositions for treating hematological disorders |
| US7470709B2 (en) | 2002-08-23 | 2008-12-30 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| DE60333487D1 (de) | 2002-12-13 | 2010-09-02 | Genetix Pharmaceuticals Inc | Therapeutische retrovirus-vektoren für gentherapie |
| CA2519975C (en) | 2003-04-08 | 2013-07-02 | Yeda Research And Development Co. Ltd | Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same |
| WO2004098531A2 (en) * | 2003-05-05 | 2004-11-18 | Virxsys Corporation | Increased transduction using abc transporter substrates and/or inhibitors |
| US6747037B1 (en) | 2003-06-06 | 2004-06-08 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| IL158868A0 (en) | 2003-11-13 | 2004-05-12 | Yeda Res & Dev | Methods of generating and using stem cells enriched with immature primitive progenitor |
| JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| WO2006047476A2 (en) | 2004-10-26 | 2006-05-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| US20080021078A1 (en) | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
| US20070087988A1 (en) | 2005-09-30 | 2007-04-19 | New York University | Hematopoietic progenitor kinase 1 for modulation of an immune response |
| US8076315B2 (en) | 2005-10-14 | 2011-12-13 | The Board Of Trustees Of The University Of Illinois | Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists |
| DE102005062741A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Fluorene und Carbazole als Liganden des EP2 Rezeptors |
| CA2647201C (en) | 2006-03-24 | 2016-03-08 | Children's Medical Center Corporation | Method to modulate hematopoietic stem cell growth |
| WO2007124578A1 (en) * | 2006-04-27 | 2007-11-08 | Universite De Montreal | Assessment and reduction of risk of graft-versus-host disease |
| EP2049129B1 (en) | 2006-06-22 | 2013-06-12 | Yeda Research And Development Co., Ltd. | Catecholamine receptor modulation |
| EP3824885A1 (en) | 2006-10-20 | 2021-05-26 | Children's Medical Center Corporation | Method to enhance tissue regeneration |
| US9394520B2 (en) | 2006-12-08 | 2016-07-19 | University Of Rochester | Expansion of hematopoietic stem cells |
| ES2703592T3 (es) | 2007-03-07 | 2019-03-11 | Mei Pharma Inc | Combinación de agente anticancerígeno de bencimidazol y un segundo agente anticancerígeno |
| WO2008126932A2 (en) | 2007-04-09 | 2008-10-23 | Riken | Epigenetical regulation of brain plasticity |
| CN108379292A (zh) * | 2008-11-06 | 2018-08-10 | 印第安纳大学研究与技术公司 | 增强造血干细胞植入过程的材料和方法 |
| EP2408444A4 (en) | 2009-03-19 | 2012-09-26 | Fate Therapeutics Inc | COMPOSITIONS WITH CYCLIC AMP AMPLIFIERS AND / OR EP LIGANDS, AND METHOD FOR THEIR PRODUCTION AND USE |
| US11459545B2 (en) * | 2009-11-15 | 2022-10-04 | Indiana University Research And Technology Corporation | Methods to enhance delivery and engraftment of stem cells including the identification of specific prostaglandin E2 receptors |
| SG11201401077PA (en) * | 2011-09-30 | 2014-04-28 | Bluebird Bio Inc | Compounds for improved viral transduction |
| WO2014015318A1 (en) * | 2012-07-19 | 2014-01-23 | Bluebird Bio, Inc. | Soluble compounds for improved gene therapy methods |
| US20150216903A1 (en) * | 2012-08-10 | 2015-08-06 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| US9943545B2 (en) * | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
| KR20160075676A (ko) * | 2013-10-24 | 2016-06-29 | 오스페달레 산 라파엘 에스.알.엘. | 방법 |
| CN103937743B (zh) * | 2014-04-27 | 2017-12-01 | 浙江大学 | 一种利用三维诱导系统获得造血干细胞的方法 |
| US10669528B2 (en) * | 2015-06-25 | 2020-06-02 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| BR112018001232A2 (pt) * | 2015-07-21 | 2018-09-25 | The Children's Medical Center Corporation | pd-l1 que expressa células-tronco hematopoéticas e usos |
| US11326183B2 (en) * | 2016-02-12 | 2022-05-10 | Bluebird Bio, Inc. | VCN enhancer compositions and methods of using the same |
| EP3414321B8 (en) * | 2016-02-12 | 2023-05-03 | bluebird bio, Inc. | Vcn enhancer compositions and methods of using the same |
| GB201706394D0 (en) * | 2017-04-21 | 2017-06-07 | Ospedale San Raffaele Srl | Gene Therapy |
| FR3074189A1 (fr) * | 2017-11-30 | 2019-05-31 | Assistance Publique - Hopitaux De Paris | Methode de generation de greffons de cellules souches hematopoietiques |
-
2012
- 2012-09-28 SG SG11201401077PA patent/SG11201401077PA/en unknown
- 2012-09-28 MX MX2014003923A patent/MX359398B/es active IP Right Grant
- 2012-09-28 DK DK12836507.9T patent/DK2760994T4/da active
- 2012-09-28 JP JP2014533413A patent/JP6285863B2/ja active Active
- 2012-09-28 UA UAA201403867A patent/UA114796C2/uk unknown
- 2012-09-28 DK DK17173567.3T patent/DK3269802T3/da active
- 2012-09-28 ES ES12836507T patent/ES2632444T5/es active Active
- 2012-09-28 CN CN201810168851.5A patent/CN108220246B/zh not_active Expired - Fee Related
- 2012-09-28 EA EA201490627A patent/EA032699B1/ru unknown
- 2012-09-28 EP EP22161134.6A patent/EP4095236A1/en not_active Withdrawn
- 2012-09-28 CA CA2850484A patent/CA2850484C/en active Active
- 2012-09-28 US US14/348,572 patent/US9988644B2/en active Active
- 2012-09-28 AU AU2012315699A patent/AU2012315699B2/en not_active Ceased
- 2012-09-28 PT PT171735673T patent/PT3269802T/pt unknown
- 2012-09-28 CN CN201280056851.7A patent/CN103958667A/zh active Pending
- 2012-09-28 EP EP12836507.9A patent/EP2760994B2/en active Active
- 2012-09-28 ES ES17173567T patent/ES2769270T3/es active Active
- 2012-09-28 BR BR112014007782-7A patent/BR112014007782B1/pt not_active IP Right Cessation
- 2012-09-28 SG SG10201602423TA patent/SG10201602423TA/en unknown
- 2012-09-28 ES ES19204363T patent/ES2913633T3/es active Active
- 2012-09-28 IN IN2518CHN2014 patent/IN2014CN02518A/en unknown
- 2012-09-28 EP EP19204363.6A patent/EP3656848B1/en active Active
- 2012-09-28 KR KR1020147011495A patent/KR102011532B1/ko not_active Expired - Fee Related
- 2012-09-28 PT PT128365079T patent/PT2760994T/pt unknown
- 2012-09-28 EP EP17173567.3A patent/EP3269802B1/en not_active Revoked
- 2012-09-28 WO PCT/US2012/057987 patent/WO2013049615A1/en active Application Filing
-
2014
- 2014-03-30 IL IL231812A patent/IL231812B/en active IP Right Grant
- 2014-03-31 MX MX2018011791A patent/MX2018011791A/es unknown
-
2018
- 2018-02-02 JP JP2018017184A patent/JP6745826B2/ja not_active Expired - Fee Related
- 2018-06-04 US US15/997,643 patent/US10501759B2/en active Active
-
2019
- 2019-10-28 US US16/665,892 patent/US10907177B2/en active Active
-
2020
- 2020-01-22 CY CY20201100056T patent/CY1122654T1/el unknown
- 2020-12-17 US US17/125,930 patent/US11834668B2/en active Active
-
2021
- 2021-02-23 IL IL281045A patent/IL281045B/en unknown
-
2023
- 2023-11-30 US US18/525,721 patent/US20240229070A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN02518A (enrdf_load_stackoverflow) | ||
| WO2014026110A3 (en) | Compounds for improved viral transduction | |
| MX2013014544A (es) | Vectorales de terapia genica para adrenoleucodistrofia y adrenomieloneuropatia. | |
| MX2022003116A (es) | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. | |
| MX356525B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
| MX2019008428A (es) | Inhibidores de glucosilceramida sintasa. | |
| IN2014CN00688A (enrdf_load_stackoverflow) | ||
| WO2011159684A3 (en) | Generation of induced pluripotent stem cells from small volumes of peripheral blood | |
| TN2015000091A1 (en) | Glucosylceramide synthase inhibitors | |
| GB201020995D0 (en) | Biological materials and uses thereof | |
| MX366318B (es) | Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1. | |
| WO2013090356A3 (en) | Opsin polypeptides and methods of use thereof | |
| MX2010000348A (es) | Cultivo de celulas madre pluripotentes individuales. | |
| EP2603227A4 (en) | IMPROVED HEMATOPOETIC TRIBE AND PRECURSOR CELL THERAPY | |
| MX2014003889A (es) | Compuestos antivirales. | |
| MX2011011508A (es) | Vector genico. | |
| EA201391114A1 (ru) | Способы использования alk-ингибиторов | |
| MX344970B (es) | Medio de cultivo celular para la expresion de la proteina adamts. | |
| MX2013008212A (es) | Derivados de 7-azaindol. | |
| MX2013008192A (es) | Inhibidores de bace-2 para tratamiento de transtornos metabolicos. | |
| MX2013004061A (es) | Analogos de ciclosporina. | |
| EP3998341A3 (en) | Adenoviral vectors | |
| IN2015DN00344A (enrdf_load_stackoverflow) | ||
| MX2013004062A (es) | Analogos de ciclosporina. | |
| WO2012094193A3 (en) | Methods for enhancing the delivery of gene-transduced cells |